secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2022-02-04T23:59:59+00:00
Accession:  0001558370-22-000789
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics director Rachel Humphrey resigns, to stay as consultant
--------------------------------------------------------------------------

- Rachel Humphrey, M.D. resigned from Xilio's board effective February 3, 2022.
- Resignation was not due to any disagreement with the company or its management.
- Dr. Humphrey will continue to serve as a consultant to Xilio Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022000789/0001558370-22-000789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022000789/xlo-20220203x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-000789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer